Antipruritic treatment with systemic μ-opioid receptor antagonists: A review

Journal of the American Academy of Dermatology

Volumn 63, Issue 4, 2010, Pages 680-688

  Phan, Ngoc Quan ^a   Bernhard, Jeffrey D ^b,c   Luger, Thomas A ^a   Ständer, Sonja ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^c Logical Images Inc   (United States)

Author keywords

atopic dermatitis; itch; opioid receptor antagonist; pruritus; sensory nerve fibers; therapy

Indexed keywords

ANTIPRURITIC AGENT; BUTORPHANOL; MU OPIATE RECEPTOR ANTAGONIST; NALMEFENE; NALOXONE; NALTREXONE; MU OPIATE RECEPTOR;

ABDOMINAL PAIN; ANGIONEUROTIC EDEMA; ANOREXIA; ANXIETY; ARTHRALGIA; ATOPIC DERMATITIS; CHILL; CHRONIC URTICARIA; CLINICAL PRACTICE; DEPERSONALIZATION; DEPRESSION; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG EXCRETION; DRUG METABOLISM; DYSPNEA; FATIGUE; FEVER; HALLUCINATION; HEADACHE; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HEARTBURN; HUMAN; HYPERTENSION; LUNG EDEMA; MYALGIA; MYCOSIS FUNGOIDES; NAUSEA; NERVE FIBER; NIGHTMARE; PARESTHESIA; PRIORITY JOURNAL; PRURIGO; PRURITUS; REVIEW; RHINITIS; SENSORY NERVE; SIDE EFFECT; TREMOR; URTICARIA; VASODILATATION; VOMITING; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CHRONIC DISEASE; DOSE RESPONSE; DRUG ADMINISTRATION; FEMALE; FOLLOW UP; MALE; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ANTIPRURITICS; CHRONIC DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; NALOXONE; NALTREXONE; PRURITUS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, OPIOID, MU; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 77956719480     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2009.08.052     Document Type: Review

References (80)

1. A. Ikoma, M. Steinhoff, S. Ständer, G. Yosipovitch, and M. Schmelz The neurobiology of itch Nat Rev Neurosci 7 2006 535 547
2. S. Ständer, and M. Schmelz Chronic itch and pain-similarities and differences Eur J Pain 10 2006 473 478
3. J.D. Friedman, and F.A. Dello Buone Opioid antagonists in the treatment of opioid-induced constipation and pruritus Ann Pharmacother 35 2001 85 91
4. S.H. Ngai, B.A. Berkowitz, J.C. Yang, J. Hempstead, and S. Spector Pharmacokinetics of naloxone in rats and man Anesthesiology 44 1976 398 401
5. D.R. Jasinski, W.R. Martin, and C.A. Haertzen The human pharmacology and abuse potential of n-allylnoroxymorphone (Naloxone) J Pharmacol Exp Ther 157 1967 420 426
6. W.R. Martin, D.R. Jsinski, and P.A. Mansky Naltrexone, an antagonist for the treatment of heroin dependence Arch Gen Psychiatry 28 1973 784 791
7. M.C. Lee, H.N. Wagner, S. Tanada, J.J. Frost, A.N. Bice, and R.F. Dannals Duration of occupancy of opiate receptors by naltrexone J Nucl Med 29 1988 1207 1211
8. J.P. Gonzalez, and R.N. Brogden Naltrexone: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of opioid dependence Drugs 35 1988 192 213
9. K. Verebey, J. Volavka, S.J. Mule, and R.B. Resnick Naltrexone: disposition, metabolism and effects after acute and chronic dosing Clin Pharmacol Ther 20 1976 315 328
10. M.C. Meyer, A.B. Straughn, M.W. Lo, W.L. Schary, and C.C. Whitney Bioequivalence, dose proportionality and pharmacokinetics of naltrexone after oral administration J Clin Psychiatry 45 1984 15 19
11. E.J. Cone, C.W. Gorodetzky, and S.Y. Yeh The urinary excretion profile of naltrexone and metabolites in man Drug Metab Dispos 2 1974 506 512
12. J. Volavka, A. Mallya, J. Bauman, J. Pevnick, D. Cho, and D. Reker Hormonal and other effects of naltrexone in normal men Adv Exp Med Biol 116 1979 291 305
13. E.F. Hahn, J. Fishman, and R.D. Heilman Narcotic antagonist, 4carbon-6 derivates of Nsubstituted noroxymorphones as narcotic antagonists J Med Chem 18 1975 259 262
14. S. Kim, H.N. Wagner, V.L. Villemagne, P.F. Kao, R.F. Dannals, and H.T. Ravert Longer occupancy of opioid receptors by nalmefene compared to naloxone as measured in vivo by dual-detector systems J Nucl Med 38 1997 1726 1731
15. T.J. Gal, C.A. DiFazio, and R. Dixon Prolonged blockade of opioid effect with oral nalmefene Clin Pharmacol Ther 40 1986 537 542
16. G.R. Matzke, R.F. Frye, A.C. Alexander, R. Reynolds, R. Dixon, and J. Johnston The effect of renal insufficiency and hemodialysis on the pharmacokinetics of nalmefene J Clin Pharmacol 36 1996 144 151
17. M.E. Michel, G. Bolger, and B.A. Weissmann Binding of a new opiate antagonist, nalmefene, to rat brain membranes Methods Find Exp Clin Pharmacol 7 1985 175 177
18. A. Chumpa Nalmefene hydrochloride Pediatr Emerg Care 15 1999 141 143
19. R. Dixon, J. Gentile, H.B. Hsu, J. Hsiao, J. Howes, and D. Garg Nalmefene: safety and kinetics after single and multiple oral doses of a new opioid antagonist J Clin Pharmacol 27 1987 233 239
20. D. Metze, S. Reimann, S. Beissert, and T. Luger Efficacy and safety of naltrexone, an oral opiate receptor antagonist, in the treatment of pruritus in internal and dermatological diseases J Am Acad Dermatol 41 1999 533 539
21. N.V. Bergasa, D.W. Alling, T.L. Talbot, M.G. Swain, C. Yurdaydin, and M.L. Turner Effects of naloxone infusions in patients with the pruritus of cholestasis: A double-blind, randomized, controlled trial Ann Intern Med 123 1995 161 167
22. N.V. Bergasa, J.M. Schmitt, T.L. Talbot, D.W. Alling, M.G. Swain, and M.L. Turner Open label trial of oral nalmefene therapy for the pruritus of cholestasis Hepatology 27 1998 679 684
23. E.A. Jones, and L.R. Dekker Florid opioid withdrawal-like reactions precipitated by naltrexone in a patient with chronic cholestasis Gastroenterology 118 2000 431 432
24. E.W. Monroe Efficacy and safety of nalmefene in patients with severe pruritus caused by chronic urticaria and atopic dermatitis J Am Acad Dermatol 21 1989 135 136
25. C. Pauli-Magnus, G. Mikus, D.M. Alscher, T. Kirschner, W. Nagel, and N. Gugeler Naltrexone does not relieve uremic pruritus: results of a randomized, double-blind, placebo-controlled crossover study J Am Soc Nephrol 11 2000 514 519
26. G. Peer, S. Kivity, O. Agami, E. Fireman, D. Silverberg, and M. Blum Randomized crossover trial of naltrexone in uremic pruritus Lancet 348 1996 1552 1554
27. J.R. Sullivan, and A. Watson Naltrexone: A case report of pruritus from an antipruritic Australas J Dermatol 38 1997 196 198
28. C. Oncken, J. van Kirk, and H.R. Kranzler Adverse effects of oral naltrexone: analysis of data from two clinical trials Psychopharmacology (Berl) 154 2001 397 402
29. J.R. Burch, and P.V. Harrison Opiates, sleep and itch Clin Exp Dermatol 13 1988 418 419
30. K.L. Carson, T.T. Tran, P. Cotton, A.I. Sharara, and C.M. Hunt Pilot study of the use of naltrexone to treat the severe pruritus of cholestatic liver disease Am J Gastroenterol 91 1996 1022 1023
31. J. Neuberger, and E.A. Jones Liver transplantation for intractable pruritus is contraindicated before an adequate trial of opiate antagonist therapy Eur J Gastroenterol Hepatol 13 2001 1393 1394
32. R.L. Atkinson, L.K. Berke, C.R. Drake, M.L. Bibbs, F.L. Williams, and D.L. Kaiser Effects of long-term therapy with naltrexone on body weight in obesity Clin Pharmacol Ther 38 1985 419 422
33. J.E. Mitchell Naltrexone and hepatotoxicity Lancet 1 1986 1215
34. R.F. Frye, G.R. Matzke, R. Schade, R. Dixon, and M. Rabinovitz Effects of liver disease on the disposition of the opioid antagonist nalmefene Clin Pharmacol Ther 61 1997 15 23
35. C. Stein, H. Machelska, and M. Schäfer Peripheral analgesic and antiinflammatory effects of opioids Z Rheumatol 60 2001 416 424
36. P. Sacerdote, L. Gaspani, and A.E. Panerai The opioid antagonist naloxone induces a shift from type 2 to type 1 cytokine pattern in normal and skin-grafted mice Ann N Y Acad Sci 917 2000 755 763
37. P.A. Singleton, L. Moreno-Vinasco, S. Sammani, S.L. Wanderling, J. Moss, and J.G. Garcia Attenuation of vascular permeability by methylnaltrexone: role of mOP-R and S1P3 transactivation Am J Respir Cell Mol Biol 37 2007 222 231
38. M. Bertolotti, A. Ferrari, G. Vitale, M. Stefani, T. Trenti, and P. Loria Effect of liver cirrhosis on the systemic availability of naltrexone in humans J Hepatol 27 1997 505 511
39. J.E. Bernstein, and R.A. Grinzi Butorphanol-induced pruritus antagonized by naloxone J Am Acad Dermatol 5 1981 227
40. B. Fjellner, and Ö Hägermark Potentiation of histamine-induced itch and flare response in human skin by the enkephalin analogue FK 33-824, beta-endorphin and morphine Arch Dermatol Res 274 1982 29 37
41. M.C. Ko, and N.N. Naughton An experimental itch model in monkeys: characterization of intrathecal morphine-induced scratching and antinociception Anesthesiology 92 2000 795 805
42. T. Sakurada, S. Sakurada, S. Katsuyama, T. Hayashi, C. Sakurada, and K. Tan-No Evidence that N-terminal fragments of nociceptin modulate nociceptin-induced scratching, biting and licking in mice Neurosci Lett 279 2000 61 64
43. P.V. Scott, and H.B.J. Fischer Intraspinal opiates and itching: A new reflex? Br Med J 284 1982 1015 1016
44. D. Andrew, and A.D. Craig Spinothalamic lamina I neurons selectively sensitive to histamine: A central neural pathway for itch Nat Neurosci 4 2001 72 77
45. J.E. Bernstein, and R.M. Swift Relief of intractable pruritus with naloxone Arch Dermatol 115 1979 1366 1367
46. J.E. Bernstein, R.M. Swift, K. Soltani, and A.L. Lorincz Antipruritic effect of an opioid antagonist, naloxone hydrochloride J Invest Dermatol 78 1982 82 83
47. G. Heyer, M. Dotzer, T.L. Diepgen, and H.O. Handwerker Opiate and H1 antagonist effects on histamine induced pruritus and allokinesis Pain 73 1997 239 243
48. J.A. Summerfield Naloxone modulates the perception of itch in man Br J Clin Pharmacol 10 1980 180 183
49. T. Andoh, T. Nagasawa, M. Satoh, and Y. Kuraishi Substance P induction of itch associated response mediated by cutaneous NK1 tachykinin receptors in mice J Pharmacol Exp Ther 286 1998 1140 1145
50. T. Yamaguchi, T. Nagasawa, M. Satoh, and Y. Kuraishi Itch-associated response induced by intradermal serotonin through 5-HT2 receptors in mice Neurosci Res 35 1999 77 83
51. G.R. Heyer, and O.P. Hornstein Recent studies of cutaneous nociception in atopic and nonatopic subjects J Dermatol 26 1999 77 86
52. L.W. Andersen, M. Friedberg, and N. Lokkegaard Naloxone in the treatment of uremic pruritus: A case history Clin Nephrol 21 1984 355 356
53. E. Legroux-Crespel, J. Cldes, and L. Misery A comparative study on the effects of naltrexone and loratadine on uremic pruritus Dermatology 208 2004 326 330
54. H.S. Ghura, A.D. Patterson, and A.J. Carmichael Naltrexone in the treatment of renal itch Br J Dermatol 139 1998 64
55. W.D. Kendrick, A.M. Woods, M.Y. Daly, R.F. Birch, and C. DiFazio Naloxone versus nalbuphine infusion for prophylaxis of epidural morphine-induced pruritus Anesth Analg 82 1996 641 647
56. J.P. Penning, B. Samson, and A.D. Baxter Reversal of epidural morphine-induced respiratory depression and pruritus with nalbuphine Can J Anaesth 35 1988 559 604
57. R. Slappendel, E.W. Weber, B. Benraad, J. van Limbeek, and R. Dirksen Itching after intrathecal morphine Incidence and treatment Eur J Anaesthesiol 17 2000 616 621
58. A. Tempel, E.L. Gardner, and R.S. Zukin Neurochemical and functional correlates of naltrexone-induced opiate receptor upregulation J Pharmacol Exp Ther 232 1985 439 444
59. A.G. Dawn, and G. Yosipovitch Butorphanol for treatment of intractable pruritus J Am Acad Dermatol 54 2006 527 531
60. A. Brune, D. Metze, T.A. Luger, and S. Ständer Antipruritic therapy with the oral opioid receptor antagonist naltrexone: open, non-placebo controlled administration in 133 patients Hautarzt 55 2004 1130 1136
61. N.V. Bergasa, D.W. Alling, T.L. Talbot, M.C. Wells, and E.A. Jones Oral nalmefene therapy reduces scratching activity due to the pruritus of cholestasis: A controlled study J Am Acad Dermatol 41 1999 431 434
62. F.H. Wolfhagen, E. Sternieri, W.C. Hop, G. Vitale, M. Bertolotti, and H.R. Van Buuren Oral naltrexone treatment for cholestatic pruritus: A double-blind, placebo-controlled study Gastroenterology 113 1997 1264 1269
63. N.V. Bergasa, T.L. Talbot, D.W. Alling, J.M. Schmitt, E.C. Walker, and B.L. Baker A controlled trial of naloxone infusions for the pruritus of chronic cholestasis Gastroenterology 102 1992 544 549
64. E.A. Jones, and N.V. Bergasa The pruritus of cholestasis and the opioid system JAMA 268 1992 3359 3362
65. J.R. Thornton, and M.S. Losowsky Opioid peptides and primary biliary cirrhosis Br Med J 297 1988 1501 1504
66. R. Terg, E. Coronel, J. Sordá, A.E. Muñoz, and J. Findor Efficacy and safety of oral naltrexone treatment for pruritus of cholestasis, a crossover, double blind, placebo controlled study J Hepatol 37 2002 717 722
67. F. Mansour-Ghanaei, A. Taheri, H. Froutan, H. Ghofrani, M. Nasiri-Toosi, and A.H. Bagherzadeh Effect of oral naltrexone on pruritus in cholestatic patients World J Gastroenterol 12 2006 1125 1128
68. Y. Chang, and L. Golkar The use of naltrexone in the management of severe generalized pruritus in biliary atresia: report of a case Pediatr Dermatol 25 2008 403 404
69. S. Smitz, J.J. Legros, and M. LeMaire Naloxone, itch, asthma, urticaria and angioedema Ann Intern Med 97 1982 788 789
70. D. Banerji, R. Fox, M. Seleznick, and R. Lockey Controlled antipruritic trial of nalmefene in chronic urticaria and atopic dermatitis [abstract] J Allergy Clin Immunol 81 1988 252
71. G. Heyer, D. Groene, and P. Martus Efficacy of naltrexone on acetylcholine-induced allokinesis in atopic eczema Exp Dermatol 11 2002 448 455
72. L. LaSalle, G. Rachelska, and B. Nedelec Naltrexone for the management of post-burn pruritus: A preliminary report Burns 23 2008 797 802
73. S. Ingber, and P.D. Cohen Successful treatment of refractory aquagenic pruritus with naltrexone J Cutan Med Surg 9 2005 215 216
74. B. Wikström, R. Gellert, S.D. Ladefoged, Y. Danda, M. Akai, and K. Ide Kappa-opioid system in uremic pruritus: multicenter, randomized, double-blind, placebo-controlled clinical studies J Am Soc Nephrol 16 2005 3742 3747
75. J. Moss, and C.E. Rosow Development of peripheral opioid antagonists' new insights into opioid effects Mayo Clin Proc 83 2008 1116 1130
76. C.S. Yuan, J.F. Foss, M. O'Connor, J. Osinski, M.F. Roizen, and J. Moss Efficacy of orally administered methylnaltrexone in decreasing subjective effects after intravenous morphine Drug Alcohol Depend 52 1998 161 165
77. S. Commiskey, L.W. Fan, I.K. Ho, and R.W. Rockhold Butorphanol: effects of a prototypical agonist-antagonist analgesic on kappa-opioid receptors J Pharmacol Sci 98 2005 109 116
78. H. Lee, N.N. Naughton, J.H. Woods, and M.C. Ko Effects of butorphanol on morphine-induced itch and analgesia in primates Anesthesiology 107 2007 478 485
79. E. Dunteman, M. Karanikolas, and K.S. Filos Transnasal butorphanol for the treatment of opioid-induced pruritus unresponsive to antihistamines J Pain Symptom Manage 12 1996 255 260
80. N.V. Bergasa Treatment of the pruritus of cholestasis Curr Treat Options Gastroenterol 7 2004 501 508